Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Ribozymes02:47

Ribozymes

The term ribozyme is used for RNA that can act as an enzyme. Ribozymes are mainly found in selected viruses, bacteria, plant organelles, and lower eukaryotes. Ribozymes were first discovered in 1982 when Tom Cech’s laboratory observed Group I introns acting as enzymes. This was shortly followed by the discovery of another ribozyme, Ribonulcease P, by Sid Altman’s laboratory. Both Cech and Altman received the Nobel Prize in chemistry in 1989 for their work on ribozymes.
Ribozymes can be...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Revisiting long-standing biological questions through evolving technologies.

Bioscience trends·2026
Same author

RNA activation as a precision dosing modality: MTL-CEBPA for controlled enzyme elevation in MPS I-H.

Frontiers in medicine·2026
Same author

C/EBPβ stabilizes oxidative stress in triple-negative breast cancer cells, driving taxane resistance and immune evasion.

Molecular therapy : the journal of the American Society of Gene Therapy·2025
Same author

ASOs reduce SARS-CoV-2 viral titers in Syrian golden hamsters.

Molecular therapy. Nucleic acids·2025
Same author

A hypoxia-responsive tRNA-derived small RNA confers renal protection through RNA autophagy.

Science (New York, N.Y.)·2025
Same author

Small RNAs as therapeutic agents: From catalytic motifs to regulatory pathways.

Molecular therapy : the journal of the American Society of Gene Therapy·2025
Same journal

Erratum for the Research Article "Guanosine diphosphate-mannose suppresses homologous recombination repair and potentiates antitumor immunity in triple-negative breast cancer".

Science translational medicine·2026
Same journal

CAR T cell therapy selectively depletes disease-driving mutant calreticulin cells in xenotransplants and human organoid models of myelofibrosis.

Science translational medicine·2026
Same journal

Bioresponsive microneedle stent provides anastomosis and postoperative adjuvant therapy in preclinical resectable intestinal diseases.

Science translational medicine·2026
Same journal

Alzheimer's disease proteome-wide association study implicates adaptive immunity and identifies risk genes LILRB1 and SIRPA.

Science translational medicine·2026
Same journal

KSHV-infected endothelial cells expand and up-regulate angiogenic pathways and CXCR4 in patient-derived Kaposi sarcoma models.

Science translational medicine·2026
Same journal

Hypoxia-driven T cell-macrophage-stromal cross-talk sustains fibrosis in preclinical models of cutaneous chronic graft-versus-host disease.

Science translational medicine·2026
See all related articles

Related Experiment Video

Updated: May 21, 2026

DNAzyme 10-23 - Based Nanomachines for Nucleic Acid Recognition
07:16

DNAzyme 10-23 - Based Nanomachines for Nucleic Acid Recognition

Published on: February 9, 2024

Resurrecting DNAzymes as sequence-specific therapeutics.

John J Rossi1

  • 1Department of Molecular and Cellular Biology, Beckman Research Institute of the City of Hope, Duarte, CA 91010, USA. jrossi@coh.org

Science Translational Medicine
|June 23, 2012
PubMed
Summary
This summary is machine-generated.

A novel DNA enzyme effectively inhibited skin cancer growth in mice. This sequence-specific enzyme demonstrated potent tumor reduction with minimal side effects.

More Related Videos

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors
06:07

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors

Published on: August 5, 2022

Sequence-specific and Selective Recognition of Double-stranded RNAs over Single-stranded RNAs by Chemically Modified Peptide Nucleic Acids
09:04

Sequence-specific and Selective Recognition of Double-stranded RNAs over Single-stranded RNAs by Chemically Modified Peptide Nucleic Acids

Published on: September 21, 2017

Related Experiment Videos

Last Updated: May 21, 2026

DNAzyme 10-23 - Based Nanomachines for Nucleic Acid Recognition
07:16

DNAzyme 10-23 - Based Nanomachines for Nucleic Acid Recognition

Published on: February 9, 2024

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors
06:07

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors

Published on: August 5, 2022

Sequence-specific and Selective Recognition of Double-stranded RNAs over Single-stranded RNAs by Chemically Modified Peptide Nucleic Acids
09:04

Sequence-specific and Selective Recognition of Double-stranded RNAs over Single-stranded RNAs by Chemically Modified Peptide Nucleic Acids

Published on: September 21, 2017

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Skin cancer presents a significant global health challenge.
  • Targeted therapies are crucial for effective cancer treatment.
  • Developing novel therapeutic agents with favorable safety profiles is essential.

Purpose of the Study:

  • To evaluate the efficacy of a sequence-specific mRNA-cleaving DNA enzyme in a mouse model of skin cancer.
  • To assess the pharmacodynamic properties and safety of the DNA enzyme following intratumoral injection.

Main Methods:

  • Establishment of a mouse model for skin cancer.
  • Intratumoral administration of the sequence-specific mRNA-cleaving DNA enzyme.
  • Monitoring of tumor growth inhibition and assessment of pharmacodynamic profiles.

Main Results:

  • The DNA enzyme demonstrated potent inhibition of skin tumor growth.
  • Pharmacodynamic profiles associated with the enzyme were unusually benign.
  • The sequence-specific nature of the enzyme contributed to targeted therapeutic effects.

Conclusions:

  • Sequence-specific mRNA-cleaving DNA enzymes represent a promising therapeutic strategy for skin cancer.
  • This approach offers potent tumor growth inhibition with a favorable safety margin.
  • Further investigation into DNA enzyme therapeutics for oncological applications is warranted.